Analysts Set Teva Pharmaceutical Industries Limited (NYSE:TEVA) Target Price at $23.57

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report) has received an average rating of "Moderate Buy" from the seven brokerages that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $23.57.

Several research firms recently commented on TEVA. JPMorgan Chase & Co. raised their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a "neutral" rating in a research note on Monday, October 21st. Piper Sandler increased their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a report on Friday, January 17th. StockNews.com cut shares of Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a report on Wednesday, December 18th. UBS Group dropped their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a report on Thursday, January 30th. Finally, Barclays dropped their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th.

Insider Activity

In related news, Director Roberto Mignone sold 286,000 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the completion of the sale, the director now directly owns 695,000 shares in the company, valued at $15,296,950. This trade represents a 29.15 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the sale, the executive vice president now owns 44,104 shares of the company's stock, valued at $744,034.48. This trade represents a 30.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.55% of the company's stock.

Institutional Trading of Teva Pharmaceutical Industries

Institutional investors have recently bought and sold shares of the stock. Stifel Financial Corp boosted its stake in Teva Pharmaceutical Industries by 54.0% in the 3rd quarter. Stifel Financial Corp now owns 66,391 shares of the company's stock worth $1,196,000 after purchasing an additional 23,283 shares in the last quarter. Robeco Institutional Asset Management B.V. boosted its stake in Teva Pharmaceutical Industries by 7.2% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company's stock worth $10,983,000 after purchasing an additional 33,277 shares in the last quarter. Thrivent Financial for Lutherans raised its position in Teva Pharmaceutical Industries by 21.8% during the 3rd quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company's stock worth $4,046,000 after buying an additional 40,218 shares during the last quarter. Sio Capital Management LLC purchased a new position in Teva Pharmaceutical Industries during the 3rd quarter worth approximately $24,314,000. Finally, CWA Asset Management Group LLC purchased a new position in Teva Pharmaceutical Industries during the 4th quarter worth approximately $3,340,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Trading Down 0.9 %

TEVA stock traded down $0.16 during trading on Friday, hitting $16.68. The company had a trading volume of 5,223,895 shares, compared to its average volume of 12,951,582. The firm has a market capitalization of $18.89 billion, a P/E ratio of -11.49, a PEG ratio of 1.39 and a beta of 0.71. Teva Pharmaceutical Industries has a 52-week low of $12.43 and a 52-week high of $22.80. The company has a 50 day simple moving average of $20.05 and a 200-day simple moving average of $18.51. The company has a quick ratio of 0.61, a current ratio of 0.98 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, research analysts forecast that Teva Pharmaceutical Industries will post 2.62 earnings per share for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.